Functional Brands Issues Letter to ShareholdersMaking Everyone Healthy Again: A Milestone Moment and Strategic Vision for GrowthNovember 24, 2025 8:00 AM EST | Source: Functional Brands Inc.Lake Oswego, Oregon--(Newsfile Corp. - November 24, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, issued the following letter from Eric Gripentrog, Chief Executive Officer.Dear Valued Shareholders,It is with great pride and enthusiasm that I write t ...

Core Insights - Protext Mobility, Inc. has announced a strategic Letter of Intent (LOI) with TruLeaf, which is expected to accelerate technology adoption and market expansion while introducing innovative financial applications leveraging CBD-based assets [1][4] Group 1: Technological Synergy & Bioavailability - TruLeaf's nanotechnology significantly enhances Protext's kettle technology, leading to increased bioavailability, making products more effective, faster, and more affordable for patients [2][3] - The partnership reduces production costs, thereby enhancing shareholder value and supporting the mission of global healing and patient wellbeing [3] Group 2: Regulatory & Competitive Advantage - The collaboration involves THC-free CBD FECO that complies with the Farm Bill, providing a clear market differentiation and competitive edge for Protext [3] Group 3: Financial Strengthening & Asset Potential - The resulting active pharmaceutical ingredient (API) is recognized as a real-world asset (RWA) under IFRS/GAAP, which strengthens the company's balance sheet and net profit without cash outflow [3] - These RWAs could support the creation of a stablecoin, enabling new financial opportunities such as staking or investment for the company and its shareholders [3] Group 4: Market Validation & Mission Impact - TruLeaf's support serves as a vote of confidence from an established partner, which is expected to accelerate Protext's growth, operational scaling, and market entry [3] - The partnership aligns with Protext's mission of "raising all boats," aiming to improve patient outcomes and create shareholder value [4]

Lakewood, CO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) (the “Company”) reported financial results for the three and nine months ended September 30, 2025, and announced the completion of a PCAOB audit of its consolidated financial statements for the years ended December 31, 2024, and 2023. Cesar Herrera, the Company’s Chief Executive Officer, said: “We are pleased to announce that we now have PCAOB-audited financial statements for our previous two fiscal years and that there were ...

LAS VEGAS, NV / ACCESS Newswire / November 14, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in plant-based nutraceutical innovations, reported results for the third quarter and nine months ended September 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. ...

Financial Data and Key Metrics Changes - Total revenues increased 39% year-over-year to $9.1 million in Q3 2025, compared to $6.5 million in Q3 2024 [3][13] - Gross profit increased 50% to $5.6 million, representing 61% of total revenue, up from 57% in the same year-ago quarter [13][14] - Adjusted EBITDA loss narrowed to $0.4 million in Q3 2025 from a loss of $1.7 million in Q3 2024 [14] Business Line Data and Key Metrics Changes - Product revenue grew 30% to $8.4 million, while CDMO revenue surged 722% to $0.7 million [13][14] - Core capsules accounted for 88% of product revenues, with new products contributing approximately 30% of growth [4][5] Market Data and Key Metrics Changes - The US VINIA active user base exceeded 75,000 customers, contributing to revenue growth [3] - The launch of VINIA BloodFlow Hydration targets the $17 billion US electrolyte hydration market [9] Company Strategy and Development Direction - The company operates two business verticals: direct-to-consumer products and CDMO services, aiming to drive revenue from both branded products and B2B partnerships [4] - The recent capital raise of $19.9 million will fund the next growth phase, including tripling manufacturing capacity and expanding CDMO services [11][12] - The company aims to achieve adjusted EBITDA break-even by early 2026, with a focus on revenue growth and margin improvement [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA soon, emphasizing the importance of scaling operations and maintaining cost discipline [15][17] - The company is focused on executing the rollout of new products and expanding its Health Pros Affiliate Program to enhance customer acquisition [16][17] Other Important Information - The company secured a new CDMO partnership with SaffronTech to develop saffron-derived compounds, retaining a 25% ownership of the resulting product [5][6] - Gross profit margins improved due to increased manufacturing scale and improved yields [14] Q&A Session Summary Question: Expectations for the ramp-up of the new hydration product - Management indicated a staged launch with initial positive responses and expects a quarter-on-quarter ramp-up in sales, particularly after the broader launch on December 3 [19][22] Question: Update on CDMO opportunities and SaffronTech agreement - Management detailed the collaboration with SaffronTech, emphasizing a fast-tracked development process and the potential for a quick market entry [24][26] Question: Progress on existing CDMO contracts - Management provided updates on ongoing CDMO agreements, highlighting progress in the cosmetic fragrance space and the Tate & Lyle agreement [32][33] Question: Long-term outlook for CDMO business - Management projected that by 2027-2028, approximately 75% of revenue could come from the CDMO business, with margins significantly higher than the product business [47][49] Question: Early success with the HealthPros program - Management reported strong early engagement and conversion rates from HealthPros, with plans to onboard 300 professionals by year-end [41][43]

Core Insights - The company reported a nearly 20% year-over-year increase in total revenue, driven by higher bulk sales and strong online channel performance [3] - There was a significant improvement in gross margin due to increased production volumes, which lowered cost per unit and enhanced overall efficiency [3] - Price increases for Nutrex-branded products contributed to margin expansion, despite challenges from tariffs affecting contract extraction competitiveness [3] Financial Performance - Total revenue increased by nearly 20% year-over-year [3] - Improvement in gross margin was noted as production volumes increased [3] - Price increases earlier in the year for Nutrex-branded products aided in margin expansion [3] Operational Focus - The company emphasized operational excellence and disciplined cost control to build a stronger, more resilient business [3] - There is a commitment to long-term success despite external challenges such as tariffs [3]

Group 1 - Healthy Extracts Inc. has been invited to present at the annual fall Trickle Research Microcap Conference [1] - The conference will take place at Topgolf Centennial in Centennial, Colorado on November 13, 2025 [1] - A live stream of the conference will be available on the day of the event [1]

Core Insights - HBC reported total operating revenues of NOK 54.9 million in Q3 2025, down from NOK 67.9 million in the same period last year, attributed to lower commodity prices and a weaker U.S. dollar [1] - The company experienced an EBITDA of NOK -21.1 million, with operational EBITDA at NOK -12.9 million, excluding non-recurring costs [2] - Cash and cash equivalents decreased by NOK 2.6 million, ending at NOK 65.5 million, while total liquidity, including credit facilities, was NOK 67.0 million at quarter-end [3] Financial Performance - The Midsund plant processed 5,288 tonnes of raw material, marking the highest quarterly volume in HBC's history, with a gross margin improvement to 35% from 28% [8] - Human Nutrition B2B sales surged by 200% year-over-year, driven by products like OmeGo® and ProGo®, which also won the NutraIngredients-USA "Healthy Aging" Award [8] - Consumer & Pet Health (B2C) revenues grew by 30%, supported by new European listings and product extensions [8] Product Development and Innovation - HBC focuses on sustainability and optimal utilization of natural resources, converting salmon industry by-products into health-improving ingredients [4] - Key products include ProGo®, OmeGo®, and CalGo® / NT-II®, which have shown various health benefits, including improved iron metabolism and bone health [5][6] - HBC has established academic partnerships and secured patents for its discoveries, leading to the formation of HBC Immunology, which is developing therapeutics for prostate and ovarian cancer [6] Market Position and Strategy - HBC is listed on Oslo Børs under the ticker "HBC" and emphasizes scientific evidence in its product development [7] - The company aims to enhance its equity and liquidity position following a successful private placement in October 2025 [3]

Group 1: BETA Technologies - BETA Technologies went public on November 4, raising $1.015 billion by issuing 29.85 million shares at an initial price of $34 per share [3] - On its first trading day, BETA's stock opened at $34, reached a high of $38.33, and closed at $36, marking a 5.88% increase and a total market capitalization of $7.88 billion [1] - The company specializes in the development of electric vertical takeoff and landing (eVTOL) aircraft, including related electric propulsion systems and charging solutions [4] Group 2: Functional Brands - Functional Brands listed on NASDAQ through a direct listing, offering over 150 health supplement products, including probiotics, vitamins, and amino acids [4] - For the first half of 2025, Functional Brands reported revenue of $342,000, a slight decrease from $349,000 in the same period the previous year, with a net loss of $35,000 compared to a profit of $700 [4] Group 3: SPACs - Cantor Equity Partners V (CEPV) and Westin Acquisition (WSTNU) are both special purpose acquisition companies (SPACs) that entered NASDAQ, raising $220 million and $50 million, respectively [4] - CEPV, based in New York, aims to target acquisitions in financial services, digital assets, healthcare, real estate services, technology, and software sectors [5] - Westin Acquisition, headquartered in Singapore, plans to focus on companies in the Asia-Pacific region with significant growth potential [5]

Core Insights - The article discusses the potential of consumer defensive stocks, highlighting those with more than 50% upside potential in the current market environment [5][10]. Group 1: Market Analysis - Michel Lerner from UBS emphasizes the importance of focusing on quality defensive stocks rather than solely on value stocks, which may carry higher risks in uncertain economic conditions [2][3]. - Defensive stocks, particularly in Europe, have underperformed, resembling trends seen during the dot-com bubble, but are now presenting more attractive valuations [3][4]. - Earnings pressures for some defensive stocks are beginning to ease, providing a hedge in a risk-on market environment [4]. Group 2: Stock Recommendations - JBS N.V. (NYSE:JBS) has an analyst upside of 51.40% with a price target set at $20 by Bank of America Securities, despite recent adjustments to EBITDA and EPS forecasts due to challenges in the US chicken market [10][11][12]. - BioHarvest Sciences Inc. (NASDAQ:BHST) shows an analyst upside of 51.52% and has entered a strategic agreement with Saffron Tech to develop saffron-derived compounds, aiming for large-scale production and direct-to-consumer marketing [13][15][16].